🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — August 08, 2026

The August 8, 2026 contract digest reveals $929.2 million in total obligations, entirely from civilian agencies with zero defense-related awards, underscoring a pronounced non-DOD spending pattern. The dominant theme is federal immigration enforcement and health research services, led by a $228.5 million GEO Group subsidiary award from ICE for alternative-to-detention technology and a $110.9 million SOS International translation services contract for the DOJ immigration court system. The highest-conviction signal is SAIC’s $96.2 million DHS/CBP IT support delivery order, which carries a potential $741.7 million ceiling if all options are exercised, offering substantial upside for a publicly traded contractor. A key risk is the heavy concentration in civilian immigration-related contracts, which are vulnerable to policy shifts or budget reallocations under a new administration or continuing resolution.

8 total filings
· daily

Contract Deobligations Alert — August 08, 2026

This digest covers eight contracts totaling $929.2 million, all from civilian agencies, with zero defense-related obligations—underscoring a shift in federal spending toward health, immigration enforcement, and IT modernization. The highest-conviction signal is SAIC’s $96.2 million DHS/CBP IT support award (potential value $741.7 million if all options are exercised), which adds a low-risk, time-and-materials revenue stream to SAIC’s backlog and reinforces DHS’s commitment to technology modernization. A key watch item is the concentration of high-value awards to ICE and DHS suppliers (B.I. Incorporated, SAIC), which exposes contractors to political and budgetary risks tied to immigration policy and continuing resolution uncertainty. Overall, the digest reveals strong civilian agency demand for alternative-to-detention programs, IT services, and health research, but no defense tailwinds.

8 total filings
· daily

Contract Option Exercises — August 08, 2026

This digest of 8 contract option exercises totaling $929.2 million reveals a purely civilian federal procurement landscape with zero defense-related awards, underscoring a pronounced shift toward homeland security, health research, and IT modernization spending. The Department of Homeland Security dominates with three awards worth $422.3 million, led by a $228.5 million ICE alternative-to-detention contract to GEO Group subsidiary B.I. Incorporated and a $96.2 million CBP IT support award to SAIC. The highest-conviction bullish signals come from SAIC’s low-risk time-and-materials DHS contract with a potential $741.7 million ceiling and Westat’s cost-plus NIH PATH study contract offering long-term revenue visibility through 2036. Key risks include the fixed-price performance burden on GEO Group’s ISAP contract and the near-completion status of SOS International’s $110.9 million DOJ translation award, limiting near-term upside. Investors should monitor DHS budget continuity under the next CR and the VA’s EHR modernization option exercise for Accenture Federal Services.

8 total filings
· daily

Federal Professional Services Contracts — August 08, 2026

This digest covers a single $114.4 million civilian contract awarded to Parsons Government Services Inc. by the Department of Labor for engineering services, with no defense-related awards in the period. The contract is a firm-fixed-price, full-and-open competition win, with 82% of the value already outlayed, indicating it is nearing completion. The highest-conviction signal is neutral, reflecting a stable but mature revenue stream for Parsons. Key risks include the contract's January 2024 end date and potential re-compete uncertainty, while the civilian sector theme highlights stable but non-growth-oriented DOL spending on engineering services.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — August 08, 2026

The August 8, 2026 federal IT and cybersecurity contract stream totals $302.9 million across three awards, all from civilian agencies (VA, DHS/FEMA, DHS/CBP), with zero defense-related contracts. The dominant theme is civilian IT modernization, particularly healthcare IT (VA EHR) and homeland security IT services. The highest-conviction signal is SAIC's $96.2 million DHS/CBP IT support award, which carries a potential value of $741.7 million and a bullish signal strength of 7/10. Key risks include execution risk on Accenture Federal Services' VA EHR delivery order (time-and-materials, $0 current outlay) and the relatively short performance period on IBM's FEMA contract. Investors should watch for option exercises and budget allocations, especially given the ongoing Continuing Resolution environment affecting civilian agencies.

3 total filings
· daily

All HHS Contracts — August 08, 2026

The single contract in this digest, a $85.5 million obligation to Westat, Inc. from the National Institutes of Health (NIH), represents a purely civilian health research award with no defense exposure. This cost-plus-fixed-fee contract for the Population Assessment of Tobacco and Health (PATH) study provides Westat with a low-risk, long-term revenue stream through 2030 (with potential extension to 2036), signaling strong competitive positioning in health R&D services. The highest-conviction signal is the contract's low pricing risk and stable revenue visibility, though the key risk is the reliance on future NIH budget allocations for option exercise, which could be impacted by broader federal fiscal pressures.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — August 08, 2026

This digest covers four mega contracts ($100M+) totaling $562.96 million, all from civilian agencies with zero defense-related awards, signaling a notable absence of DOD spending in this period. The dominant theme is federal immigration enforcement and legal support, with the Department of Homeland Security (ICE) and Department of Justice (EOIR) accounting for $339.4 million (60% of total), driven by GEO Group subsidiary B.I. Incorporated's $228.5 million ISAP award—the highest-conviction bullish signal. A key risk is the concentration of awards in immigration-related services, which are politically sensitive and subject to policy shifts, while the VA's EHR modernization contract with Accenture Federal Services ($109.1 million) highlights civilian IT spending but carries execution risk with zero outlays to date.

4 total filings
· daily

High-Value Federal Grants ($5M+) — August 08, 2026

This digest covers 8 high-value federal grants totaling $929.2 million, all from civilian agencies with zero defense-related awards. The dominant theme is the Department of Homeland Security (DHS), which accounts for three contracts worth $422.3 million combined, split between ICE alternative-to-detention services ($228.5M to B.I. Incorporated/GEO Group) and CBP/FEMA IT and data services ($193.8M combined to SAIC and IBM). The highest-conviction bullish signal is SAIC’s $96.2M DHS IT support delivery order with a potential value of $741.7M if all options are exercised, offering a multi-year low-risk (time-and-materials) revenue stream. A key risk is the high concentration of contract value in immigration enforcement and disaster preparedness, which are subject to policy shifts and continuing resolution uncertainty in late 2025.

8 total filings
· daily

General Federal Contracts — August 08, 2026

This digest covers $929 million in civilian-agency contract obligations from August 8, 2026, with zero defense-related awards. ICE’s $228.5 million ISAP award to B.I. Incorporated (GEO Group) is the highest-conviction signal, reinforcing GEO’s moat in immigration detention alternatives. DHS IT support to SAIC ($96.2M, with $741.7M potential) and NIH’s PATH study award to Westat ($85.5M, with $780.5M potential) provide strong, low-risk revenue streams. However, five of eight contracts are neutral signals, reflecting high competition, aging performance periods, or private parent companies—limiting near-term market catalysts. The dominant civilian theme is immigration enforcement technology and health research IT, but budget uncertainty under a potential Continuing Resolution (CR) and ICE policy changes are key risks.

8 total filings
· daily

All NASA Contracts — August 08, 2026

This digest covers a single NASA contract awarded to Guardians of Honor, LLC valued at $86.98 million obligated out of a $233 million ceiling, representing a civilian agency education support services award with no defense-related content. The contract is a firm fixed-price (FFP) structure, offering margin upside but execution risk for this small business, and carries a neutral signal strength of 6/10 with low materiality. The sole award provides near-term revenue visibility of ~$29M annually through October 2025, but the lack of competitive moat and concentration risk in a single task order warrants monitoring. Key risk is the company's ability to manage fixed-price cost overruns given its small business status, while the opportunity lies in potential option exercises under the IDIQ vehicle.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — August 07, 2026

This digest covers a single $88.2 million firm-fixed-price contract awarded to Suffolk Construction Company by the Department of Veterans Affairs for boiler replacement and control upgrades at a VA hospital in West Roxbury, MA. The award is entirely civilian (VA) and represents a competitively won infrastructure project with a three-year performance period. The highest-conviction signal is neutral, reflecting stable revenue visibility offset by fixed-price execution risk and competitive margin pressure. Key risks include potential cost overruns on a fixed-price contract and the lack of follow-on awards, while the opportunity lies in monitoring VA capital construction spending for similar infrastructure upgrades.

1 total filings
· daily

VA Healthcare & Services Contracts — August 07, 2026

The sole contract in this digest is an $88.2 million firm-fixed-price award from the Department of Veterans Affairs (VA) to Suffolk Construction Company for boiler replacement and control upgrades at a hospital in West Roxbury, MA. This is a purely civilian (VA) infrastructure project, with no defense-related content, and represents a stable but low-growth signal for the construction sector. The contract, won under full-and-open competition, provides Suffolk Construction with moderate revenue visibility over a three-year period (2026-2029), but carries execution risk due to the fixed-price nature. The highest-conviction signal is the VA's continued investment in legacy infrastructure, which may indicate a steady pipeline for construction firms but also highlights the lack of high-tech or defense-driven opportunities in this stream. Key risks include potential cost overruns on the fixed-price contract and the VA's budget sensitivity to continuing resolutions.

1 total filings
· daily

Biotech Small-Cap Approvals — August 07, 2026

The August 7, 2026 digest covers three biosimilar (FALLBACK) approvals with no NMEs, biosimilars, or label expansions, resulting in a neutral signal mix. The dominant theme is generic/biosimilar entry into established markets, with approvals for SACUBITRIL (UMEDICA), NINTEDANIB ESYLATE (MACLEODS PHARMS LTD), and INDOCYANINE GREEN (ZYDUS LIFESCIENCES). The highest-conviction signal is the SACUBITRIL biosimilar approval for UMEDICA, which introduces competition in the heart failure space, though commercial data is undisclosed. A key watch item is the lack of disclosed peak sales, exclusivity, or pricing power, limiting near-term investment conviction.

3 total filings
· daily

NME Blockbuster Approvals — August 07, 2026

This digest covers a single FDA approval event on August 7, 2026, comprising one NME approval (Oveporexton by Takeda Pharma USA) with no biosimilars or label expansions. The dominant therapeutic area is not clearly defined from this single event, but the approval of Oveporexton (ORZEYFUL) under Priority Review signals a high-unmet-need indication. The highest-conviction signal is bullish for Takeda, given the NME status and Priority Review designation, which historically correlate with strong commercial potential. A key watch item is the lack of disclosed peak sales estimates, exclusivity, and pricing power, which limits full investment assessment.

1 total filings
· daily

Big Pharma Approvals — August 07, 2026

During this single-day period, the FDA approved one NME, OVEPOREXTON (ORZEYFUL) from Takeda Pharmaceuticals USA, under Priority Review, signaling a bullish event for the sponsor. No biosimilars or label expansions were approved, making this a focused, high-signal approval. The dominant therapeutic area theme is not explicitly stated but the NME designation and Priority Review suggest a significant unmet medical need. The highest-conviction signal is Takeda's NME approval, which strengthens its pipeline credibility and commercial portfolio. Key risk is the lack of disclosed commercial data (peak sales, pricing, exclusivity), which limits full investment assessment.

1 total filings
· daily

New Drug Approvals (Original) — August 07, 2026

The August 7, 2026 FDA approval digest features 4 total approvals with zero NMEs, zero biosimilars, zero label expansions, and 4 'Other' designations, indicating a quiet period for novel therapeutic catalysts. The sole bullish signal comes from Takeda Pharmaceuticals USA's NME approval of Oveporexton (ORZEYFUL), granted Priority Review, signaling strong unmet need and potential commercial differentiation despite undisclosed peak sales estimates. The remaining three approvals are neutral biosimilar entries from Umedica (Sacubitril), Macleods Pharma (Nintedanib Esylate), and Zydus Lifesciences (Indocyanine Green), which introduce competitive pressure on originator franchises but lack disclosed pricing or market position data. Key risk: the absence of NME approvals outside Takeda's single asset limits sector-wide pipeline conviction for this period, while biosimilar approvals for Sacubitril and Nintedanib Esylate could erode originator revenues in cardiovascular and pulmonary markets respectively. Investors should monitor Takeda's launch execution for Oveporexton as the highest-conviction signal, and watch for payer coverage decisions on the biosimilars to gauge revenue erosion magnitude.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — August 07, 2026

During the period August 7, 2026, a single HHS contract worth $155.8 million was awarded to Merck Sharp & Dohme LLC for ERVEBO procurement, a civilian biodefense and pandemic preparedness action. The contract is entirely civilian (0% defense-related) and carries a moderate signal strength of 6/10 due to the firm-fixed-price structure and multi-year option uncertainty. The highest-conviction signal is Merck’s long-term revenue visibility from a 10-year base-plus-options vehicle, but investors should watch execution risk if production costs exceed the fixed price and the timing of option exercises totaling $17.8 million.

1 total filings
· daily

New Federal Contractors — August 07, 2026

This digest of 7 new federal contracts, totaling $1.26 billion, reveals a pronounced civilian agency tilt, with only 2 of 7 awards being defense-related. The dominant theme is sustained U.S. government investment in health security and biodefense, led by two substantial awards to Merck Sharp & Dohme LLC from HHS/BARDA totaling $392.1 million. The highest-conviction signal is Merck's dual contract wins, which provide long-term revenue visibility through 2034 and align with enduring pandemic preparedness priorities. A key risk is the concentration of awards to a single entity (Merck) and the absence of defense-related signals, which may limit exposure to growth in the defense budget. Investors should watch for the exercise of Merck's $72.9 million in combined contract options as a key catalyst.

7 total filings
· daily

Significant Contract Modifications ($10M+) — August 07, 2026

The 7 contracts analyzed, valued at $1.26 billion aggregate, are overwhelmingly civilian-agency awards (5 of 7), with the Department of Health and Human Services (HHS) emerging as the dominant spender via two Merck Sharp & Dohme contracts totaling $392.2 million for biodefense and pharmaceutical procurement. The highest-conviction bullish signal is Merck's dual HHS/BARDA awards, reflecting durable government biodefense funding, while the sole defense-related contract—Whitney Bradley & Brown's $108 million GSA delivery order—is neutral but exposes Serco Limited's subsidiary to firm-fixed-price execution risk. Key risks include the expiration of the ARCTIC SLOPE Technical Services $388.5 million NASA contract (fully performed, zero future upside) and concentration at HHS. Investors should monitor option exercises on Merck's BARDA contract through 2034 and Suffolk Construction's execution of a fixed-price $88.2 million VA boiler replacement project.

7 total filings
· daily

Contract Deobligations Alert — August 07, 2026

The seven contracts analyzed, totaling $1.26 billion, are overwhelmingly civilian (5 of 7), with the Department of Health and Human Services (HHS) and its BARDA agency dominating the award value via two large contracts to Merck Sharp & Dohme LLC worth $392.2 million combined. The highest-conviction signal is the dual Merck awards, which provide long-term, low-risk revenue visibility from a key biodefense agency, though the cost-plus structure on the larger award limits profit upside. A key risk is the concentration of awards to Merck, which creates single-entity dependency for the biodefense theme, and the completed nature of the largest contract (Arctic Slope Technical Services) means its revenue is non-recurring.

7 total filings